Loading...
•
Jun 30
Mirum Pharmaceuticals Q2 2025 Earnings Report
Mirum Pharmaceuticals' Q2 2025 financial results were reported, highlighting strong commercial program performance, particularly in international business and U.S. PFIC launch, leading to increased full-year revenue guidance.
Key Takeaways
Mirum Pharmaceuticals reported strong second quarter 2025 financial results, with total revenue reaching $127.8 million, driven by robust global net product sales, especially from LIVMARLI. The company raised its full-year revenue guidance to $490 million to $510 million, reflecting confidence in its commercial momentum and pipeline advancements.
Total revenue for Q2 2025 was $128 million, demonstrating significant growth compared to the previous year.
Global net product sales reached $127.8 million, with LIVMARLI sales contributing $88.2 million, an 87% increase year-over-year.
Mirum Pharmaceuticals increased its 2025 revenue guidance to a range of $490 million to $510 million.
The company is advancing its pipeline with key clinical milestones expected in 2026, including topline data for the Volixibat VISTAS study in PSC.
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Mirum Pharmaceuticals Revenue by Segment
Revenue by Segment
Product Sales, Net Revenue
CapyFin.comLIVMARLI Net Product Sales Revenue
CapyFin.comBile Acid Medicines Net Product Sales Revenue
CapyFin.com Forward Guidance
Mirum Pharmaceuticals has increased its full-year 2025 revenue guidance to a range of $490 million to $510 million, reflecting strong commercial performance and confidence in its global market penetration for LIVMARLI. The company also anticipates several key late-stage clinical milestones in 2026.
Positive Outlook
- Increased 2025 revenue guidance to $490 million to $510 million, up from previous projections.
- LIVMARLI's global momentum reinforces belief in reaching more patients than initially projected.
- Volixibat VISTAS study in PSC expected to complete enrollment this quarter, with topline data in Q2 2026.
- Volixibat VANTAGE study in PBC expected to complete enrollment in 2026.
- LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The report does not detail potential challenges in achieving the increased revenue guidance.
- No specific risks or delays were mentioned for the upcoming clinical milestones.
- The report does not provide guidance on future profitability or net income.
- No information on potential impacts of market competition or regulatory changes on future performance.